Press Releases Choose Year All Items 2025 2024 Search Press Releases Found 10 Results October 14, 2025 LB Pharmaceuticals Appoints James Rawls, Pharm.D., as Senior Vice President of Regulatory Affairs October 6, 2025 LB Pharmaceuticals to Present Three Posters at 38th ECNP Congress Highlighting Clinical Activity and Safety Profile of LB-102 in Schizophrenia, Including Positive Effects on Cognition and Negative Symptoms September 25, 2025 LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani September 10, 2025 LB Pharmaceuticals Announces Pricing of its Upsized Initial Public Offering March 31, 2025 LB Pharmaceuticals Presents New Data from Phase 2 Clinical Trial of LB-102 at the 2025 Annual Congress of the Schizophrenia International Research Society February 11, 2025 LB Pharmaceuticals Announces Key Executive Appointments to Support Growth and Late-Stage Development of LB-102 January 8, 2025 LB Pharmaceuticals Announces Positive Topline Results from Phase 2 Trial of LB-102 in Schizophrenia January 6, 2025 UPDATE – LB Pharmaceuticals Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference January 6, 2025 LB Pharmaceuticals Announces Presentation at the 43rd Annual J.P. Mogan Healthcare Conference November 19, 2024 LB Pharmaceuticals Names Heather Turner as CEO to Lead its Development of Transformative Advances in Schizophrenia Treatment
